Neuronetics : Supplemental Financial and Operating Information

Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended June 30, 2022

			2020				2021
Revenue ($ thousands)	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
NeuroStar Capital	$2,410	$2,224	$2,438	$3,446	$1,589	$2,441	$2,277	$2,513
Total U.S. NeuroStar Advanced Therapy System Revenues	$2,594	$2,338	$2,541	$3,620	$1,755	$2,577	$2,612	$2,815
YoY Change	-23%	-49%	-45%	-33%	-32%	10%	3%	-22%
Total U.S. Treatment Sessions Revenues	$8,193	$6,547	$9,083	$11,029	$9,629	$10,801	$10,259	$11,245
YoY Change	-7%	-40%	-11%	-2%	18%	65%	13%	2%
Total U.S. Other Revenues	$390	$382	$404	$397	$419	$431	$409	$496
YoY Change	-7%	-8%	-5%	6%	7%	13%	1%	25%
Total U.S. Revenues	$11,177	$9,267	$12,029	$15,046	$11,802	$13,809	$13,280	$14,556
YoY Change	-11%	-42%	-21%	-12%	6%	49%	10%	-3%
Total International Revenues	$299	$474	$419	$533	$486	$394	$519	$466
YoY Change	64%	-31%	-41%	64%	63%	-17%	24%	-13%
Total Revenues	$11,476	$9,741	$12,448	$15,579	$12,288	$14,203	$13,799	$15,022
YoY Change	-10%	-41%	-22%	-10%	7%	46%	11%	-4%
			2020				2021
U.S. Operating and Financial Metrics	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Total NeuroStar Systems	38	35	39	54	23	36	40	48
YoY Change	-12%	-43%	-43%	-31%	-39%	3%	3%	-11%
Average Revenue Per Active Site ($) (1)	$9,418	$7,406	$10,218	$12,133	$10,512	$12,001	$11,163	$12,183
YoY Change	-24%	-50%	-22%	-10%	12%	62%	9%	0.4%

(1) Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)

	2022	2020	2021
Q1		Q2	FY	FY

$3,485	$4,272	$10,518	$8,820
$3,642	$4,382	$11,094	$9,760
108%	70%	-38%	-12%
$9,469	$11,295	$34,852	$41,933
-2%	5%	-15%	20%
$406	$455	$1,574	$1,754
-3%	6%	-4%	12%

$13,517 $16,132 $47,519 $53,447

15% 17% -22% 12%

$664	$198	$1,725	$1,865
36%	-50%	-9%	8%

$14,181 $16,329 $49,244 $55,312

15%		15%	-21%	12%
	2022	2020	2021
Q1		Q2	FY	FY
46		59	166	147

100% 64% -34%-11%

$9,874 $11,280

-6%-6%